Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903684 | 0.83 | HRH3 (0.34) | CALM1KMT2AALDH1A1 | |
| SCHEMBL13146337 | 0.80 | CHRM2 (0.60) | KDM4EKMT2AALDH1A1POLB | |
| SCHEMBL8803380 | 0.78 | CALM1 (0.51) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL244070 | 0.75 | CALM1 (0.79) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL4254058 | 0.75 | CALM1 (0.72) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL11007798 | 0.73 | CALM1 (0.69) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL17400406 | 0.73 | CALM1 (0.69) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL9509173 | 0.73 | CALM1 (0.69) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL10571532 | 0.73 | CALM1 (0.69) | CALM1TAAR1IGF1RALOX15ALOX5 | |
| SCHEMBL10697670 | 0.73 | CALM1 (0.50) | CALM1TAAR1IGF1RALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598240-B2 | Benzothiazin-3-one compound and intermediate therefor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20080058321-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058321-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | HDAC11, HDAC8, MMP11 | CALM1 3545/4885TAAR1 4526/4885IGF1R 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.